XOMA Royalty (XOMA) Cash from Investing Activities Growth (3y) (2013 - 2026)
XOMA Royalty (XOMA) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
- |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
116.52% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
- |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
38.24% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
XOMA Royalty |
5.48 Mn |
-60.60 Mn |
- |
42.70% |
| Date | Value |
|---|
| Mar 31, 2026 |
42.70% |
| Dec 31, 2025 |
48.41% |
| Sep 30, 2025 |
1,208.22% |
| Mar 31, 2025 |
-10.21% |
| Dec 31, 2024 |
-82.43% |
| Sep 30, 2024 |
49.78% |
| Mar 31, 2024 |
18.73% |
| Dec 31, 2023 |
209.18% |
| Sep 30, 2022 |
26.03% |
| Mar 31, 2022 |
-155.44% |
| Dec 31, 2020 |
-143.85% |
| Sep 30, 2019 |
-183.98% |
| Jun 30, 2019 |
-413.41% |
| Mar 31, 2019 |
-113.10% |
| Dec 31, 2017 |
-85.17% |
| Sep 30, 2017 |
-26.10% |
| Jun 30, 2017 |
-56.85% |
| Mar 31, 2017 |
164.92% |
| Dec 31, 2016 |
89.39% |
| Sep 30, 2016 |
70.56% |
